Brentuximab Vedotin in patients with refractory/relapsed (r/r) systemic anaplastic large cell lymphoma (sALCL) and Hodgkin lymphoma (HL) : A real life experience
Phase of Trial: Phase IV
Latest Information Update: 13 Jan 2017
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Anaplastic large cell lymphoma; Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 13 Jan 2017 New trial record.
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.